Skip to main content
. Author manuscript; available in PMC: 2017 May 25.
Published in final edited form as: J Vitreoretin Dis. 2017 Jan 26;1(1):65–74. doi: 10.1177/2474126416683299

Figure 3.

Figure 3

Patient 3 is a 74 year-old pseudophakic man with neovascular AMD and active subfoveal CNV with persistent intra-retinal fluid despite multiple bevacizumab (n=15) and aflibercept (n=15) intravitreal injections. Patient underwent injection of intravitreal ranibizumab (A) with minimal change in fluid appearance on OCT after 1 month (B). Then, combined intravitreal ranibizumab and dexamethasone intravitreal implant were given with complete resolution of the intraretinal fluid (C). As a result, no anti-VEGF treatment was given at this visit and patient continued to do well with observation alone at 1 month (D) and 3 months (E) post-combined treatment without anti-VEGF injections. At that time, additional combined intravitreal ranibizumab and dexamethasone intravitreal implant were given, and patient followed at monthly intervals for 1 year with stable visual acuity without requiring additional anti-VEGF or dual therapy re-treatment (F). The best corrected visual acuity remained stable at 20/50.